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Follow-On Biologics, Patient Safety and Policy,
Focus of JSPH Program in DC
National Press Club
April 21, 2009
On April 21st, JSPH sponsored an event at the
National Press Club in Washington, DC entitled:
“Regulation of Follow-on Biologics: Ensuring Quality
and Patient Safety.” Supported by an unrestricted
educational grant from sanofi-aventis, the event
brought together a wide range of experts in
the medical field including doctors, scientists,
economists and others who discussed the quality
and safety issues surrounding the creation of a
regulatory pathway to bring follow-on biologic drugs
to market in the United States.
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Featured speakers included: Michael McCaughan,
Editor in Chief of the Pink Sheet; Ann Witt, JD, Health
Counsel to Rep. Henry A. Waxman; Brian Harvey,
MD, PhD, VP, Regulatory Policy, sanofi-aventis; Terry
Hisey, Vice Chairman, U.S. Life Sciences Leader,
Deloitte LLP; and Geno Merli, MD, FACP, FHM, Chief
Medical Officer, Thomas Jefferson University Hospital
and Director, Jefferson Center for Vascular Diseases at
Jefferson Medical College.
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Research and development costs for biologics
are very high and, as a result, therapy with these
agents for patients with chronic diseases is very
expensive. Because these products are derived by
modifying living organisms, the end product is
especially sensitive to damage or contamination,
and small differences in the manufacturing
process may have unforeseen and unintended
effects on therapeutic action.
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There is a movement to spur the development of
“follow-on” biologics (FOBs) similar to the original
products in an effort to improve access and lower
overall costs to the health care system. Congress is
intent on passing legislation enabling the Food and
Drug Administration (FDA) to develop a regulatory
pathway for FOBs similar to the pathway for generic
forms of traditional drugs. Well crafted legislation for
FOBs will afford an opportunity to reduce drug costs
and make better quality healthcare more affordable
for millions of American families.
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Currently, there are competing bills under
consideration in the House; one authored by Rep.
Henry A. Waxman (D-Calif.), Chairman of the
House Energy and Commerce Committee, and the
other drafted by Rep. Anna Eshoo (D-Calif.). In the
Senate, Charles Schumer (D-NY) has introduced a
companion to the Waxman proposal.
At the conference, there was broad support for greater
accessibility of FOBs. However, significant concerns
were expressed for patient-safety,“interchangeability”
problems and product testing issues that must be
thoroughly addressed.
Some key themes on patient safety which emerged
from the event are as follows:
1. Patient safety must be the number one priority,
including adequate safety testing prior to the
approval of any FOB.
2. The US should adopt some of the more successful
and proven provisions of European regulation, such
as its clarity around the circumstances and extent of
testing required of FOBs.
3. An FOB approval pathway must be comprehensive
and recognize the complex nature of all biologic
medications,includingproteinsandpolysaccharides.
4. Biologic efficacy is not the same as biologic
effectiveness. FOBs must be evaluated for patient
outcomes.
The outcome of this debate is likely to have farreaching implications with regard to access, cost, safety,
and therapeutic impact for thousands of patients with
serious, life-threatening, and chronic diseases. 
The conference webcast has been archived and can be
accessed online at:
www.visualwebcaster.com/FOB-Policy-Forum.

